Cargando…

Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study

OBJECTIVE: To develop a prognostic model for post-transjugular intrahepatic portosystemic shunt (TIPS) patients with hepatocellular carcinoma (HCC) beyond the Milan criteria treated by transarterial chemoembolization (TACE). DESIGN: Between January 2013 and January 2020, 512 patients with HCC beyond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Wenzhe, Zhu, Bowen, Yue, Shufan, Zheng, Xinlin, Yuan, Guosheng, Yu, Lei, Huang, Wanchang, Huang, Shugui, Wei, Wenjiang, Li, Fuliang, Huang, Zhen, Tang, Rong, Fan, Huishuang, Li, Zhuoyong, Qiao, Liangliang, Huang, Fuxi, Cheng, Yu, Zhang, Yingqiang, Wu, Yanqin, Zou, Xinhua, Xue, Miao, Wang, Hongyu, Li, Jiaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017639/ https://www.ncbi.nlm.nih.gov/pubmed/36562786 http://dx.doi.org/10.1007/s00330-022-09249-6

Ejemplares similares

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE
por: Wang, Hongyu, et al.
Publicado: (2022)

Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study
por: Zhang, Yingqiang, et al.
Publicado: (2019)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC
por: Chuang, Yi-Hsuan, et al.
Publicado: (2023)

Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma
por: Wang, Yu, et al.
Publicado: (2016)

Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy
por: Fan, Wenzhe, et al.
Publicado: (2016)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma
por: Zhang, Yingqiang, et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Fan, Wenzhe, et al.
Publicado: (2015)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy
por: Hu, Ze-Xin, et al.
Publicado: (2023)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
por: Huang, Wu-Kui, et al.
Publicado: (2017)

The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience
por: Cui, Wei, et al.
Publicado: (2017)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Decreased WWOX expression promotes angiogenesis in osteosarcoma
por: Wen, Jia, et al.
Publicado: (2017)

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus
por: Yang, Biao, et al.
Publicado: (2018)

Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Wang, Hongyu, et al.
Publicado: (2020)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases
por: Lu, Haohao, et al.
Publicado: (2022)

Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients
por: Jia, Kefeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_to5imes0ul1e8diikdbm1mqlhm